Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection

European Journal of Clinical Investigation

Volumn 34, Issue 1, 2004, Pages 57-66

  Huigen, M C D G ^a   Kamp, W ^b   Nottet, H S L M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Fight for Life Foundation   (Netherlands)

Author keywords

Acquired immunodeficiency syndrome; Gene expression; HIV 1 trans activator (Tat) protein; Human immunodeficiency virus type 1 (HIV 1); Immune regulation

Indexed keywords

CELL ADHESION MOLECULE; CELL PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; FAS ANTIGEN; FIBRONECTIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VIRUS PROTEIN;

DEMENTIA; DISEASE ASSOCIATION; DRUG POTENCY; GENE EXPRESSION REGULATION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; KAPOSI SARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; STATISTICAL SIGNIFICANCE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS TRANSCRIPTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; AIDS VACCINES; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; MODELS, GENETIC; SARCOMA, KAPOSI; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 1242269845     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01282.x     Document Type: Review

References (111)

1. Janeway CA, Travers P, Walport M, Capra JD. Failures of host defense mechanisms. In: Walport M, Capra JD, editors. Immunobiology: the Immune System in Health and Disease, 4th edn. London: Elsevier Science Ltd; 1999.p.417-59.
2. Cotran RS, Kumar V, Collins T. Diseases of immunity. In: Cotran RS, Kumar V, Collins T, editors. Robbins Pathologic Basis of Disease, 6th edn. London: W.B. Saunders Co; 1999.pp.188-259.
3. Barre-Sinoussi F. HIV as the cause of AIDS. Lancet 1996;348:31-5.
4. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998;95:3851-6.
5. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999;96:8324-6.
6. Sodroski J, Rosen C, Wong-Staal F, Salahuddin SZ, Popovic M, Arya S et al. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 1985;227:71-3.
7. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986;44:941-7.
8. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986;320:367-71.
9. Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994;63:717-43.
10. Malim MH, Hauber J, Fenrick R, Cullen BR. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 1988;335:181-3.
11. Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucl Acids Res 1989;17:3551-61.
12. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999;274:28837-40.
13. Brake DA, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990;111:1275-81.
14. Bayer P, Kraft M, Ejchart A, Westendorp M, Frank R, Rosch P. Structural studies of HIV-1 Tat protein. J Mol Biol 1995;247:529-35.
15. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-93.
16. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-87.
17. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987;330:489-93.
18. Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989;59:283-92.
19. Laspia MF, Rice AP, Mathews MB. Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. Genes Dev 1990;4:2397-408.
20. Ghosh S, Selby MJ, Peterlin BM. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR. J Mol Biol 1993;234:610-9.
21. Marciniak RA, Sharp PA. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J 1991;10:4189-96.
22. Karn J, Tackling Tat. J Mol Biol 1999;293:235-54.
23. Feinberg MB, Baltimore D, Frankel AD. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 1991;88:4045-9.
24. Bohan CA, Kashanchi F, Ensoli B, Buonaguro L, Boris-Lawrie KA, Brady JN. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 1992;2:391-407.
25. Veschambre P, Simard P, Jalinot P. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J Mol Biol 1995;250:169-80.
26. Taube R, Fujinaga K, Wimmer J, Barboric M, Peterlin BM. Tat transactivation. A model for the regulation of eukaryotic transcriptional elongation. Virology 1999;264:245-53.
27. Parada CA, Roeder RG. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 1996;384:375-8.
28. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan DO et al. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev 1997;11:2645-57.
29. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J et al. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989;86:6925-9.
30. Romano G, Kasten M, De Falco G, Micheli P, Khalili K, Giordano A. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression. J Cell Biochem 1999;75:357-68.
31. Tao J, Chen L, Frankel AD. Dissection of the proposed base triple in human immunodeficiency virus TAR RNA indicates the importance of the Hoogsteen interaction. Biochemistry 1997;36:3491-5.
32. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II. candidate for a Tat cofactor. J Virol 1995;69:1612-20.
33. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997;11:2622-32.
34. Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997;11:2633-44.
35. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998;92:451-62.
36. Garber ME, Wei P, Kewa Ramani VN, Mayall TP, Herrmann CH, Rice AP et al. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev 1998;12:3512-27.
37. Fujinaga K, Taube R, Wimmer J, Cujec TP, Peterlin BM. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci USA 1999;96:1285-90.
38. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998;280:1880-4.
39. Harrich D, Ulich C, Gaynor RB. A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription. J Virol 1996;70:4017-27.
40. Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB. Tat is required for efficient HIV-1 reverse transcription. EMBO J 1997;16:1224-35.
41. Ulich C, Dunne A, Parry E, Hooker CW, Gaynor RB, Harrich D. Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. J Virol 1999;73:2499-508.
42. Kameoka M, Morgan M, Binette M, Russell RS, Rong L, Guo X et al. The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. J Virol 2002;76:3637-45.
43. Kameoka M, Rong L, Gotte M, Liang C, Russell RS, Wainberg MA. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol 2001;75:2675-83.
44. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-6.
45. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001;276:3254-61.
46. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000;6:1380-7.
47. Sastry KJ, Reddy HR, Pandita R, Totpal K, Aggarwal BB. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990;265:20091-3.
48. Ehret A, Li-Weber M, Frank R, Krammer PH. The effect of HIV-1 regulatory proteins on cellular genes: depression of the IL-2 promoter by Tat. Eur J Immunol 2001;31:1790-9.
49. Westendorp MO, Li-Weber M, Frank RW, Krammer PH. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994;68:4177-85.
50. Vacca A, Farina M, Maroder M, Alesse E, Screpanti I, Frati L et al. Human immunodeficiency virus type-1 tat enhances interleukin-2 promoter activity through synergism with phorbol ester and calcium-mediated activation of the NF-AT cis-regulatory motif. Biochem Biophys Res Commun 1994;205:467-74.
51. Purvis SF, Georges DL, Williams TM, Lederman MM. Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell Immunol 1992;144:32-42.
52. Puri RK, Leland P, Aggarwal BB. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits interleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995;11:31-40.
53. Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997;275:1481-5.
54. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 1997;272:14883-92.
55. Nabell LM, Raja RH, Sayeski PP, Paterson AJ, Kudlow JE. Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor alpha gene in an epidermal growth factor-dependent manner. Cell Growth Differ 1994;5:87-93.
56. Cupp C, Taylor JP, Khalili K, Amini S. Evidence for stimulation of the transforming growth factor beta 1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene 1993;8:2231-6.
57. Mahieux R, Lambert PF, Agbottah E, Halanski MA, Deng L, Kashanchi F et al. Cell cycle regulation of human interleukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol 2001;75:1736-43.
58. Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 2000;74:10551-62.
59. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997;90:1535-44.
60. Taylor JP, Cupp C, Diaz A, Chowdhury M, Khalili K, Jimenez SA et al. Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA 1992;89:9617-21.
61. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995;375:497-500.
62. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M et al. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 1995;86:3823-34.
63. Li CJ, Wang C, Friedman DJ, Pardee AB. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995;92:5461-4.
64. Flores SC, Marecki JC, Harper KP, Bose SK, Nelson SK, McCord JM. Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells. Proc Natl Acad Sci USA 1993;90:7632-6.
65. Poggi A, Rubartelli A, Zocchi MR. Involvement of dihydropyridine- sensitive calcium channels in human dendritic cell function. Competition by HIV-1 Tat. J Biol Chem 1998;273:7205-9.
66. Howcroft TK, Strebel K, Martin MA, Singer DS. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 1993;260:1320-2.
67. Weissman JD, Brown JA, Howcroft TK, Hwang J, Chawla A, Roche PA et al. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci USA 1998;95:11601-6.
68. Verhoef K, Bauer M, Meyerhans A, Berkhout B. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. AIDS Res Hum Retroviruses 1998;14:1553-9.
69. Matsui M, Warburton RJ, Cogswell PC, Baldwin AS Jr, Frelinger JA. Effects of HIV-1 Tat on expression of HLA class I molecules. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:233-40.
70. Brown JA, Howcroft TK, Singer DS. HIV Tat protein requirements for transactivation and repression of transcription are separable. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:9-16.
71. Mudhasani R, Fontes JD. Inhibition of class II trans-activator function by HIV-1 tat in mouse cells is independent of competition for binding to cyclin T1. Mol Immunol 2002;38:539-46.
72. Chang HK, Gallo RC, Ensoli B. Regulation of cellular gene expression and function by the Human Immunodeficiency Virus Type 1 Tat protein. J Biomed Sci 1995;2:189-202.
73. Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 1993;36:57-64.
74. Ho WZ, Ayyavoo V, Srinivasan A, Stinski MF, Plotkin SA, Gonczol E. Human immunodeficiency virus type 1 tat gene enhances human cytomegalovirus gene expression and viral replication. AIDS Res Hum Retroviruses 1991;7:689-95.
75. Chowdhury M, Taylor JP, Chang CF, Rappaport J, Khalili K. Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat. J Virol 1992;66:7355-61.
76. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988;55:1179-88.
77. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997;94:8116-20.
78. Huang L, Li CJ, Pardee AB. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochem Biophys Res Commun 1997;237:461-4.
79. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997;159:4077-83.
80. Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 1998;72:8952-60.
81. Secchiero P, Zella D, Capitani S, Gallo RC, Zauli G. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol 1999;162:2427-31.
82. Benelli R, Barbero A, Ferrini S, Scapini P, Cassatella M, Bussolino F et al. Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. J Infect Dis 2000;182:1643-51.
83. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995;92:4838-42.
84. Benelli R, Mortarini R, Anichini A, Giunciuglio D, Noonan DM, Montalti S et al. Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. AIDS 1998;12:261-8.
85. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998;95:13153-8.
86. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol 1996;157:974-7.
87. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 1996;156:1638-45.
88. Mitola S, Sozzani S, Luini W, Primo L, Borsatti A, Weich H et al. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 1997;90:1365-72.
89. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-5.
90. Chirivi RG, Taraboletti G, Bani MR, Barra L, Piccinini G, Giacca M et al. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood 1999;94:1747-54.
91. Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S et al. Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem 1998;273:15895-900.
92. Cohen SS, Li C, Ding L, Cao Y, Pardee AB, Shevach EM et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 1999;96:10842-7.
93. Viscidi RP, Mayur K, Lederman HM, Frankel AD. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;246:1606-8.
94. Benjouad A, Mabrouk K, Moulard M, Gluckman JC, Rochat H, Van Rietschoten J et al. Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1). FEBS Lett 1993;319:119-24.
95. Zocchi MR, Rubartelli A, Morgavi P, Poggi A. HIV-1 Tat inhibits human natural killer cell function by blocking 1-type calcium channels. J Immunol 1998;161:2938-43.
96. Tardieu M, Hery C, Peudenier S, Boespflug O, Montagnier L. Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion. Ann Neurol 1992;32:11-7.
97. Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, Ma M et al. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 1998;82:97-106.
98. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 1998;54:19-33.
99. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-5.
100. Re MC, Furlini G, Vignoli M, Ramazzotti E, De Roderigo G, De R et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:408-16.
101. Marasco WA, LaVecchio J, Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Meth 1999;231:223-38.
102. Ensoli B, Cafaro A. HIV-1 Tat vaccines. Virus Res 2002;82:91-101.
103. Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol 1998;1:293-8.
104. Gringeri A, Santagostino E, Muca-Perja M, Le Buanec H, Bizzini B, Lachgar A et al. Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:371-5.
105. Silvera P, Richardson MW, Greenhouse J, Yalley-Ogunro J, Shaw N, Mirchandani J et al. Outcome of simian-human immunodeficiency virus strain 89. 6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 2002;76:3800-9.
106. Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000;97:3515-9.
107. Berkhout B, Gatignol A, Rabson AB, Jeang KT. TAR-independent activation of the HIV-1 LTR. Evidence that tat requires specific regions of the promoter. Cell 1990;62:757-67.
108. Taylor JP, Pomerantz R, Bagasra O, Chowdhury M, Rappaport J, Khalili K et al. TAR-independent transactivation by Tat in cells derived from the CNS. a novel mechanism of HIV-1 gene regulation. EMBO J 1992;11:3395-403.
109. Yang L, Morris GF, Lockyer JM, Lu M, Wang Z, Morris CB. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat. Virology 1997;235:48-64.
110. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996;17:369-72.
111. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV-1 Tat: a polypeptide for all seasons. Immunol Today 1998;19:543-5.